GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Kilitch Drugs India Ltd

Kilitch Drugs India Q2 FY27 Standalone Net Profit at Rs. 410.19 Lakhs

RESULTS ◆ Monitor Closely MEDIUM RISK
📅 Filed on BSE: 06 Nov 2026, 08:43 PM IST  ·  BSE ID: 45e1b573-10a6-4f35-8db7-8da2d9e764ee
View Original BSE Filing (PDF)
💡
In Simple Terms
The company released its latest financial results and announced a plan to convert debt into equity and sell its Ethiopian subsidiary.
🤖 AI Summary
  • Kilitch Drugs India Ltd approved Q2 FY27 standalone and consolidated unaudited financial results.
  • Standalone Net Sales from Operations for Q2 FY27 were Rs. 4,349.26 Lakhs, with Net Profit after Tax at Rs. 410.19 Lakhs.
  • Consolidated Net Sales from Operations for Q2 FY27 reached Rs. 5,021.50 Lakhs.
  • Company approved converting Rs. 57.00 crore outstanding debt in Kilitch Estro Biotech PLC into equity shares.
  • Kilitch Drugs also approved divesting its entire shareholding in Kilitch Estro Biotech PLC for USD 14.00 million.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Standalone Net Sales/Income from operations (Q2 FY27)
Rs. 4,349.26 Lakhs
15.02%
Standalone Net Profit / (Loss) after Tax (Q2 FY27)
Rs. 410.19 Lakhs
-52.93%
Consolidated Net Sales/Income from Operations (Q2 FY27)
Rs. 5,021.50 Lakhs
14.32%
Consolidated Net Profit / (Loss) after Tax (Q2 FY27)
Rs. 433.80 Lakhs
-30.59%
Divestment consideration for Kilitch Estro Biotech PLC
USD 14.00 million
🏢 How This Affects the Company
📈
Business Impact
The divestment of Kilitch Estro Biotech PLC suggests a strategic focus adjustment, potentially streamlining international operations. The conversion of debt to equity precedes the divestment, indicating a clean-up of the subsidiary's financials before sale.
💰
Financial Impact
Consolidated Net Profit after Tax for Q2 FY27 was Rs. 433.80 Lakhs. The divestment of the Ethiopian subsidiary is expected to bring in USD 12.855 million payable to the company, affecting cash and investment balances upon completion.
⚙️
Operational Impact
The divestment of Kilitch Estro Biotech PLC will simplify the company's operational structure by removing an overseas subsidiary. This transaction is subject to regulatory approvals and statutory compliances.
⚠️
Risk Impact
The divestment reduces the company's direct exposure to the Ethiopian market. However, completion of the transaction is subject to compliance with FEMA and other applicable laws, and regulatory approvals.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required by shareholders based on this financial results and divestment announcement.
👤
Who Is Affected
All shareholders are affected by the operational and financial performance reflected in the unaudited results. The divestment of the material subsidiary, Kilitch Estro Biotech PLC, affects the company's asset base and future revenue streams.
🔍
Management Signal
The Board's decision to convert debt into equity in a subsidiary followed by its divestment signals a strategic move to optimize international assets and streamline the business, subject to regulatory processes.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Regulatory approvals for Kilitch Estro Biotech PLC divestment.
Progress on USD 12.855 million payment receipt from the divestment.
Q3 FY27 financial results to assess ongoing performance and cash flow.
MEDIUM RISK Divestment completion is contingent on regulatory approvals, potentially introducing execution risks.
💡 Investor Takeaway
Kilitch Drugs India reported Q2 FY27 standalone Net Sales of Rs. 4,349.26 Lakhs and Net Profit after Tax of Rs. 410.19 Lakhs. The company also announced the conversion of Rs. 57.00 crore debt in its Ethiopian subsidiary and subsequent divestment for USD 14.00 million, pending approvals.
⚖️ Strengths & Concerns

✅ Positives

  • Standalone Net Sales from Operations for the six months ended September 30, 2026, increased to Rs. 8,440.46 Lakhs from Rs. 7,193.55 Lakhs.
  • Total Comprehensive Income (after taxes) on a standalone basis for Q2 FY27 was Rs. 276.88 Lakhs, with six-month total at Rs. 1,282.34 Lakhs.

⚠️ Concerns

  • Standalone Net Profit after Tax for Q2 FY27 decreased to Rs. 410.19 Lakhs compared to Rs. 871.57 Lakhs in Q2 FY26.
  • Consolidated Net Profit after Tax for Q2 FY27 was Rs. 433.80 Lakhs, a decrease from Rs. 624.96 Lakhs in Q2 FY26.
📅 Company Track Record
Kilitch Drugs India Ltd previously informed BSE on May 7, 2026, about a Board Meeting scheduled for May 15, 2026, to approve audited financial results. This current filing details Q2 FY27 unaudited results and a significant subsidiary divestment.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What was Kilitch Drugs India's standalone Net Sales in Q2 FY27?
Kilitch Drugs India reported standalone Net Sales/Income from Operations of Rs. 4,349.26 Lakhs for the quarter ended September 30, 2026.
What was Kilitch Drugs India's standalone Net Profit after Tax for Q2 FY27?
The standalone Net Profit after Tax for Kilitch Drugs India for Q2 FY27 was Rs. 410.19 Lakhs, compared to Rs. 871.57 Lakhs in Q2 FY26.
What is the update regarding Kilitch Drugs India's subsidiary, Kilitch Estro Biotech PLC?
Kilitch Drugs India has approved converting an outstanding debt of up to Rs. 57.00 crore in Kilitch Estro Biotech PLC into equity, and subsequently divesting its entire shareholding for an aggregate consideration of USD 14.00 million.
What is the cash flow from operating activities for Kilitch Drugs India for the six months ended September 30, 2026?
The Net cash flow from operating activities for Kilitch Drugs India for the six months ended September 30, 2026, was Rs. 317.49 Lakhs.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.